NCT06978621View on ClinicalTrials.gov

Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV

PHASE3RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

May 25, 2025

Primary Completion Date

August 31, 2025

Study Completion Date

September 30, 2025

Conditions
Hepatitis AHepatitis A VirusVaccine-Preventable Diseases
Interventions
BIOLOGICAL

Inactivated hepatitis A vaccine (I-HAV)

"A formaldehyde-inactivated hepatitis A virus (HM175 hepatitis A virus strain)~Dose and administration: 0.5 mL intramuscular injection for participants age \<=18 years, and 1.0 mL intramuscular injection for participants age 19 years and above."

Trial Locations (1)

50200

RECRUITING

Department of Pediatrics, Faculty of Medicine, Chiang Mai University, Chiang Mai

All Listed Sponsors
collaborator

Faculty of Medicine, Chiang Mai University

UNKNOWN

lead

Chiang Mai University

OTHER